Antinuclear Antibodies
ANA
Description
"Antinuclear Antibodies" (ANA) test measures antibodies that mistakenly target cells' nuclei, often seen in autoimmune conditions like lupus or rheumatoid arthritis. Doctors use this test when symptoms like joint pain, fatigue, or unexplained rashes raise concern. High ANA levels suggest immune dysfunction and prompt further testing. While not diagnostic by itself, ANA testing supports early identification of autoimmune disorders. Results help doctors guide additional evaluation and create a personalized care plan based on immune activity and clinical presentation.
Test Category
Autoantibodies
Procedure
Invasive
Sample Type
Blood – Serum
Units
Ratio
Procedure Category
Blood Draw
Test Group
Chronic Illness Group, Autoimmune Condition Group
Test Group Description
Chronic Illness Group: This group encompasses a range of tests specifically tailored to assess markers associated with chronic health conditions, providing comprehensive insights into the management and monitoring of chronic illnesses. Autoimmune Condition Group: Tests within this group focus on markers associated with autoimmune diseases, providing insights into the body's immune response against its own tissues.
Optimal Range
For All Individuals:
Conventional Unit: Not Available
SI Unit: Not Applicable
Normal Range
For All Individuals:
Conventional Unit: 1:40–1:60 R
SI Unit: Not Applicable
Results That Differ From The Norm (Direct and Indirect Causes)
Increased levels may indicate:
Chronic hepatitis (Long-term inflammation of the liver)
Cirrhosis (Scarring of the liver)
Dermatomyositis (Inflammatory disease affecting the skin and muscles)
EB virus (Epstein-Barr virus, associated with infectious mononucleosis)
Hashimoto's thyroiditis (Autoimmune inflammation of the thyroid gland)
- ...
Key Reasons For Testing
Autoimmune Disease Screening: Screens for autoimmune conditions like lupus, Sjögren's syndrome, or scleroderma.
Diagnosis of Connective Tissue Diseases: Identifies conditions like lupus and mixed connective tissue disease.
Differentiating Disease Subtypes: Guides diagnosis by distinguishing between types of autoimmune diseases.
Monitoring Disease Activity: Tracks changes in disease progression or improvement.
Health Status Conditions It May Be Used To Assess
Currently, this test is not directly associated with any conditions listed on the Health Status page. However, it may be included as part of a broader set of tests linked to specific health conditions.
Some Prominent Medical Labs That May Offer This Test
Please note that this particular test has not been associated with any of the listed prominent medical labs. We recommend enquiring with your private physician or nearest hospital to determine where this specific test can be performed.
References
Important Note
Any medical procedure yielding results outside the norm may be directly or indirectly linked to the conditions outlined on this page. Various factors, including genetics, medication and supplement usage, recent illnesses, pregnancy, pre-test eating, smoking, and stress, can impact the test's outcome. Additionally, factors like false positives, false negatives, inaccurate analyses, and others can influence results.
Reference ranges, which help healthcare professionals interpret medical tests, may vary depending on age, gender, and other factors. They may also differ between laboratories due to variations in instruments and methods used. Optimal ranges are designed for preventive purposes, aiming to identify trends and potential risks early, while normal ranges reflect conventional laboratory values indicating no current disease or pathology. Your healthcare practitioner may have specific reasons for testing that deviate from the usual or may interpret results differently based on individual circumstances. Proper interpretation typically involves considering clinical findings and other diagnostic tests. Hence, it is crucial to provide your healthcare professionals with a comprehensive medical history, consult with them for result interpretation, and follow their guidance for potential re-testing or additional diagnostics.
Disclaimer
This content is provided solely for informative and educational purposes. It is not intended as a substitute for medical advice or treatment from a personal physician. Regarding the interpretation of their medical test results and/or specific health questions, it is recommended that all readers and viewers consult their physicians or other qualified health professionals. The publisher is not responsible for any adverse health effects that may result from reading or following the information in this educational content. Before beginning any nutrition, supplement, or lifestyle program, all viewers, especially those taking prescription or over-the-counter medications, should consult their physician or health care practitioner.
Please note that while prominent lab names are included in this content, we cannot guarantee that these labs offer all the tests mentioned. For confirmation, individuals should contact the labs directly or consult their medical practitioners. The information provided reflects general knowledge at the time of publication and may not include recent updates or emerging research. Readers should verify details with qualified professionals to ensure the most up-to-date and accurate guidance.
[1] Meroni PL, Schur PH. ANA screening: an old test with new recommendations. Ann Rheum Dis. 2010;69(8):1420-1422.
[2] Tan EM, Feltkamp TE, Smolen JS, et al. Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum.1997;40(9):1601-1611.
[3] Pisetsky DS. Antinuclear antibodies in rheumatic disease: a proposal for a function-based classification. Scand J Immunol. 2016;84(6):367-372.
[4] Agmon-Levin N, Damoiseaux J, Kallenberg C, et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as antinuclear antibodies. Ann Rheum Dis. 2014;73(1):17-23.
[5] Satoh M, Chan EK, Sobel ES, et al. Clinical implication of autoantibodies in patients with systemic rheumatic diseases. Expert Rev Clin Immunol. 2007;3(6):721-738.
[6] Mahler M, Hanly JG, Fritzler MJ. Importance of detecting antibodies in clinical research and practice. Lupus.2012;21(7):715-717.
[7] Solomon DH, Kavanaugh AJ, Schur PH. Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum. 2002;47(4):434-444.
[8] Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349(16):1526-1533.
[9] ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CG. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. Arthritis Rheum.1990;33(5):634-643.
[10] von Mühlen CA, Fritzler MJ, Chan EKL. Clinical and laboratory evaluation of systemic rheumatic diseases. In: McPherson RA, Pincus MR, eds. Henry's Clinical Diagnosis and Management by Laboratory Methods. 23rd ed. St Louis, MO: Elsevier; 2017:452-475.
[11] Reeves WH, Zhuang H, Han S. Autoantibodies in systemic lupus erythematosus. In: Hochberg MC, Gravallese EM, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, eds. Rheumatology. 7th ed. Philadelphia, PA: Elsevier; 2019:139-153.